Asia Will Become Strategic Imperative For Pharmaceutical Companies, Quintiles Says
This article was originally published in The Pink Sheet Daily
Pipeline pressures will make Asia a contributor to drug discovery and research innovation as well as a market and support powerhouse, the CRO says.
You may also be interested in...
Drug makers need to more aggressively target so-called "pharmerging" markets - but not just the usual suspects. Brazil, Russia, India and China remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent last year
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.